Navigation Links
Syneron Signs Multi-Year Exclusive Equipment Provider Agreement with Sono Bello Contouring Centers to Offer LipoLite(TM) and VelaShape(TM)
Date:6/10/2008

YOKNEAM, Israel, June 10 /PRNewswire-FirstCall/ -- Syneron(TM) Medical Ltd. (Nasdaq: ELOS), an innovator in the development, marketing and sales of elos(TM) combined-energy medical aesthetic devices, today announces a multi-year exclusive provider agreement with Sono Bello Contouring Centers for its LipoLite(TM) laser-assisted lipolysis device, and VelaShape(TM) cellulite and thigh circumferential reduction device.

Sono Bello Contouring Centers provide both invasive and non-invasive body contouring procedures. The company will open its first clinics in Seattle, Wash. in June, four additional U.S. locations later this year, and expects to feature 30 body contouring clinics nationwide by the end of 2010. With this agreement, Sono Bello Contouring Centers will use the LipoLite and VelaShape technology in each of the 30 clinic locations to provide the company's body contouring related services.

"After a long and thorough evaluation process, we found that Syneron's LipoLite is a better technological solution for laser-assisted lipolysis when compared to other devices on the market. In addition, Syneron provides a superior business solution to further our company's profitability and growth," said Chris Par, CEO of Sono Bello Body Contouring Centers. "The combined protocol of laser-assisted lipolysis with LipoLite and cellulite and thigh circumferential reduction with VelaShape provides more value and depth of services for our future clientele."

FDA-cleared in April, LipoLite is the only laser-assisted lipolysis device featuring OptiPulse technology, which optimizes the mechanical breakdown of target adipose tissue and the thermal destruction of fat cell membranes during procedures. OptiPulse utilizes two unique pulse energy
'/>"/>

SOURCE Syneron Medical Ltd.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Authentidate and EncounterCare Form ExpressMD Solutions Joint Venture to Provide Telehealth Vital Signs Monitoring Systems Designed to Improve Chronic Illness Care for Patients
2. Renhuang Pharmaceuticals, Inc. Holds Trade Show for Tianma Pills; Signs Letters of Intent
3. Protect Your Eyes in Style: Cinzia Designs Offers Top Tips for Protecting Your Eyes This Summer
4. Click4Care Signs Award-Winning 500,000-Member Health Plan
5. Television Star Caitlin Van Zandt Signs-on as Special Guest Speaker for National Obesity Awareness Event in Washington, DC, on June 17
6. IBC Signs New Agreements with Holy Redeemer Health System
7. Many With Heart Disease Dont Know Signs of Heart Attack
8. NeoStem Signs Stem Cell Collection Agreement With University of Louisville Hospital
9. AlphaRx Signs Cooperative Research and Development Agreement with US Army
10. Know the Warning Signs of Stroke
11. Delray Beach Soccer Club Signs Division One College Soccer Coaches
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 2Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 3Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 4Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 5Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 6Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 2Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 3Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 4Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 5Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 6Daniel K. Spiegelman Elected to Board of Directors of Omeros 2Its Time for More Moms to Breast Feed U S Officials Say 54480 1Its Time for More Moms to Breast Feed U S Officials Say 54480 2Its Time for More Moms to Breast Feed U S Officials Say 54480 3Little safe haven for sexually assaulted LGBTQ victims 54475 1Little safe haven for sexually assaulted LGBTQ victims 54475 2Little safe haven for sexually assaulted LGBTQ victims 54475 3Queen of Soul Foods Grandson on Mission to Get Harlem Kids to Eat Healthier 54472 1Queen of Soul Foods Grandson on Mission to Get Harlem Kids to Eat Healthier 54472 2Queen of Soul Foods Grandson on Mission to Get Harlem Kids to Eat Healthier 54472 3